Innova Captab Limited has announced an investor presentation for the analysts and institutional investor meeting to discuss the un-audited financial results for the quarter and nine months ended December 31, 2025. This follows their earlier intimation regarding an earnings call scheduled for January 27, 2026, at 12:00 Noon (IST). The company has provided an investor presentation for the said earnings call, which was prepared based on reliable information. The presentation includes a company overview, highlighting its position as a leading pharmaceutical player with a comprehensive business model, serving over 300 CDMO customers globally and having a presence in 60+ countries. Performance highlights for Q3 and 9M FY26 show a strong year-on-year revenue growth of 42% in Q3 and 27% in 9M FY26. This growth was driven by improved client engagement in the CDMO business and strategic geographic expansion in the branded generics vertical. Exports contributed 35% to the revenue mix in Q3 FY26. EBITDA saw a robust YoY growth of 40% in Q3 FY26, reaching ₹71.1 crore, and a 25% growth for 9M FY26, reaching ₹183.7 crore. Profit After Tax (PAT) for Q3 FY26 was ₹42.1 crore, a 23% YoY growth, and for 9M FY26, it was ₹102.8 crore, a 4% YoY growth. The company also announced receiving Certificates of GMP Compliance from UK-MHRA for its Cephalosporin, Baddi unit, and from PIC/s (SMDC, Ukraine) for its Jammu facility. The Managing Director's commentary emphasized the strong performance, disciplined execution, and commitment to stakeholder value creation. The presentation also details historical financial performance, balance sheet information, and cash flow statements.
